526 related articles for article (PubMed ID: 10590382)
21. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
23. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
24. Intensive sequential chemotherapy with hematopoietic growth factor support for non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus.
Costello RT; Zerazhi H; Charbonnier A; de Colella JM; Alzieu C; Poizot-Martin I; Cohen R; Bardou VJ; Xerri L; Olive D; Nezri M; Lepeu G; Gastaut JA
Cancer; 2004 Feb; 100(4):667-76. PubMed ID: 14770420
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
26. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma.
Wilder RB; Rodriguez MA; Ha CS; Pro B; Hess MA; Cabanillas F; Cox JD
Cancer; 2001 Jun; 91(12):2440-6. PubMed ID: 11413536
[TBL] [Abstract][Full Text] [Related]
27. How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL; Martelli M; Magagnoli M; Zaja F; Storti S; Pavone E; Lauta VM; De Renzo A; Gobbi M; Bocchia M; Ronconi F; Scaramucci L; Gherlinzoni F; Palombi F; Bendandi M; Stefoni V; Anticoli Borza P; Cellini C; Mandelli F; Tura S
Haematologica; 1999 Nov; 84(11):996-1001. PubMed ID: 10553159
[TBL] [Abstract][Full Text] [Related]
28. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
29. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
[TBL] [Abstract][Full Text] [Related]
30. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response.
Levine AM; Tulpule A; Espina B; Sherrod A; Boswell WD; Lieberman RD; Nathwani BN; Welles L
J Clin Oncol; 2004 Jul; 22(13):2662-70. PubMed ID: 15226333
[TBL] [Abstract][Full Text] [Related]
31. The length of treatment of aggressive non-Hodgkin's lymphomas established according to the international prognostic index score: long-term results of the GISL LA03 study.
Federico M; Luminari S; Gobbi PG; Sacchi S; Di Renzo N; Lombardo M; Merli F; Baldini L; Stelitano C; Partesotti G; Polimeno G; Montanini A; Mammi C; Brugiatelli M
Eur J Haematol; 2006 Mar; 76(3):217-29. PubMed ID: 16451396
[TBL] [Abstract][Full Text] [Related]
32. Quality of life assessment in elderly patients with aggressive non-Hodgkin's Lymphoma treated with anthracycline-containing regimens. Report of a prospective study by the Intergruppo Italiano Linfomi.
Merli F; Bertini M; Luminari S; Mozzana R; Bertè R; Trottini M; Stelitano C; Botto B; Pizzuti M; Quintana G; De Paoli A; Federico M;
Haematologica; 2004 Aug; 89(8):973-8. PubMed ID: 15339681
[TBL] [Abstract][Full Text] [Related]
33. [Low-grade non-Hodgkin's lymphomas. Study of 73 cases].
Coma A; Jonte F; Zanabili Y; Soto I; Fanjul F; Carrera D; Rayón C; Luño E; Jalón S; Pinto V
Sangre (Barc); 1992 Aug; 37(4):249-54. PubMed ID: 1514137
[TBL] [Abstract][Full Text] [Related]
34. Prospective analysis of treatment outcome and prognostic factors in patients with T-cell lymphomas treated by CEOP-B: single institutional study.
Sung HJ; Kim SJ; Seo HY; Sul HR; Choi JG; Choi IK; Park KH; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS
Br J Haematol; 2006 Jul; 134(1):45-53. PubMed ID: 16803566
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
[TBL] [Abstract][Full Text] [Related]
36. Combination of ifosfamide, methotrexate, and etoposide (IMVP) as a salvage therapy for relapsed and refractory aggressive non-Hodgkin lymphoma: retrospective study.
Aurer I; Duraković N; Radman I; Nemet D; Zupancić-Salek S; Kovacević-Metelko J; Bogdanić V; Sertić D; Mrsić M; Mikulić M; Labar B
Croat Med J; 2002 Oct; 43(5):550-4. PubMed ID: 12402394
[TBL] [Abstract][Full Text] [Related]
37. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
38. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
40. [Clinical analysis of 68 patients with primary gastric lymphoma].
Luo ZG; Feng FY; Zhang P; Wang XY; Wang QL
Ai Zheng; 2004 Dec; 23(12):1692-5. PubMed ID: 15601562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
